Robert Haws

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period

Andrea M. Haqq, Wendy K. Chung, Hélène Dollfus et al. · The Lancet Diabetes & Endocrinology · 2022 · 165 citations · Full text

Alström Syndrome, Pharmacology, Clinical Trials +5

Autosomal Dominant Pseudohypoaldosteronism Type 1

David S. Geller, Junhui Zhang, Maria‐Christina Zennaro et al. · Journal of the American Society of Nephrology · 2006 · 131 citations

Urology, Genetic Disorder, Medicine +15

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in <scp>Bardet‐Biedl</scp> syndrome

Robert Haws, Sheila M. Brady, Elisabeth K. Davis et al. · Diabetes Obesity and Metabolism · 2020 · 125 citations · Full text